Two clinicians analyzed 6,285 independent lab reports on gray market peptides (BPC-157, tirzepatide, retatrutide, TB-500, and ten others) submitted to the public third-party testing platform Finnrick Analytics. Judged against a lenient compounding-pharmacy benchmark, 41.6 percent of samples failed on dose accuracy, purity, or identity. Against a stricter manufactured-drug benchmark, 71.1 percent failed. Roughly 1 in 42 vials contained none of the labeled peptide at all, 15 percent of the small endotoxin-tested subset carried measurable bacterial toxin, and chromatographic purity did not predict endotoxin burden. Gray market products were far cheaper than pharmacy versions, which is the likely engine of demand.
The gray market for injectable peptides has exploded, sold through social media and e-commerce under the legal fig leaf of “research chemical, not for human consumption,” then injected by real people chasing fat loss, muscle, joint repair, and metabolic health. The obvious question, rarely answered with data, is whether the stuff in the vial matches the label. This preprint offers the largest independent look so far.
The authors did not run their own assays. Instead they mined a publicly posted dataset from Finnrick Analytics, a testing service where consumers and vendors submit vials for high performance liquid chromatography and mass spectrometry. After cleaning, 6,285 reports across 14 peptides and 203 manufacturers remained, spanning December 2024 to April 2026. They then scored each vial two ways: a lenient Compounding Standards Model (dose within 90 to 110 percent of label, purity at or above 98 percent) and a strict Manufactured Standards Model (dose 95 to 105 percent, purity at or above 99.5 percent).
The headline is uncomfortable. Under the lenient model, 41.6 percent of samples failed. Under the strict model, 71.1 percent failed. The dominant failure mode was not dirty product but wrong dose. Under the strict standard, 44.3 percent of all vials hit the purity target yet fell outside the acceptable dose window, meaning the chemistry was clean but the amount was off. Identity failures were rarer but alarming where they clustered: 1 in 10 TB-500 and CJC-1295 vials contained none of the advertised peptide.
Purity numbers looked reassuringly high across the board (overall median 99.8 percent), which is exactly the trap. In the subset with endotoxin data, 15 percent carried measurable bacterial endotoxin, and purity showed no relationship to that contamination (R squared under 0.01). A spotless chromatogram tells you nothing about whether the injection is pyrogen-free.
Quality also tracked the maker, not just the molecule. Among the top 20 vendors, some consistently landed inside both quality windows across multiple peptides while others consistently missed, regardless of compound. In a regulated system, facility inspection and batch release testing catch this. Here, none of that exists.
Why do people buy anyway? Price. A 24-week course of PT-141 ran about 122 dollars gray market versus 4,819 dollars for the FDA-approved product, a roughly 39-fold gap. The big idea is blunt: independent testing adds welcome transparency, but a purity certificate clears only two of the ten-plus hurdles a real drug must pass, so a “tested” vial is still largely an unknown injected into the body.
Actionable Insights
Take-home one, expect a coin flip at best. Under a lenient pharmacy-style standard, the failure rate was 41.6 percent (about 1 in 2.4 vials fails). Under a strict standard it was 71.1 percent (about 5 in 7 fail). Effect size framing: baseline probability that a random gray market vial is out of spec sits between 0.42 and 0.71 depending on how strict you are.
Take-home two, dose is the problem, not just purity. Under the strict model, 44.3 percent of vials were pure but off-dose. You are more likely to get the wrong amount than dirty product, so self-titrating a gray market peptide as if the label is accurate is the core risk.
Take-home three, some vials are empty. Identity failure was 2.4 percent overall but reached 10.0 percent for TB-500 and 9.1 percent for CJC-1295. Relative risk of a blank vial for TB-500 versus the pooled average is about 4.2. One in ten is not a rounding error.
Take-home four, purity does not equal sterility. 15 percent of endotoxin-tested vials had measurable endotoxin (0.5 to 40 EU/mL), and purity did not predict it (R squared under 0.01). If you inject, a purity COA is not a pyrogen clearance. Test endotoxin separately or do not assume safety.
Take-home five, the savings are real but so is the reason for them. PT-141 gray market cost was about 97 percent below the FDA product (39-fold), tirzepatide about 42 percent below (1.73-fold). That price gap reflects the absence of the very quality infrastructure that would have caught the failures above.
Context and Source
- Open Access Paper: Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance.
- Authors and institution: Christopher L. Mendias and Tariq M. Awan, Performance Medicine Institute, Phoenix, Arizona, United States.
- Venue: Preprints.org (operated by MDPI, Basel, Switzerland)
- Impact evaluation: Preprints.org is a preprint server, not a peer-reviewed journal